Search results for "immunosuppressive agent"

showing 10 items of 282 documents

Novel Signal Transduction Pathways: Analysis of STAT-3 and Rac-1 Signaling in Inflammatory Bowel Disease

2006

Although the precise etiology of inflammatory bowel disease still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. Augmented T cell resistance against apoptosis is regarded as a pivotal factor in the pathogenesis, as it impairs mucosal homeostasis and leads to unrestrained accumulation of activated T cells, which subsequently lead to the amplification of the inflammatory response. Therefore novel therapeutic strategies aim at restoring mucosal T cell susceptibility to apoptosis through targeting of signal transduction pathways that a…

STAT3 Transcription Factorrac1 GTP-Binding ProteinT-LymphocytesT cellApoptosisTherapeutic ProcedureAzathioprineBiologyInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular BiologystatPathogenesisHistory and Philosophy of ScienceAzathioprinemedicineHumansGeneral NeuroscienceInflammatory Bowel Diseasesmedicine.diseasemedicine.anatomical_structureApoptosisImmunologySignal transductionImmunosuppressive AgentsSignal Transductionmedicine.drugAnnals of the New York Academy of Sciences
researchProduct

Systematic review: macrophage activation syndrome in inflammatory bowel disease.

2013

Summary Background Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if diagnosed rapidly, is high. Aim To identify all reports on MAS in IBD and to establish data on triggering agents, immunosuppression leading to MAS, and mortality. Methods A language unrestricted search on Pubmed and Scopus relating to the past 30 years was carried out by matching the following search-terms: h(a)emophagocytic lymphohistiocytosis OR h(a)emophagocytic lym…

Settore MED/09 - Medicina Internamedicine.medical_treatmentHepatosplenomegalyDiseaseSystematic review. macrophage activation syndrome.inflammatory bowel diseaseInflammatory bowel diseaseImmunocompromised HostRisk FactorsmedicineHumansPharmacology (medical)CytopeniaHepatologyThiopurine methyltransferasebiologybusiness.industryMacrophage Activation SyndromeGastroenterologyImmunosuppressionmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisMacrophage activation syndromeImmunologybiology.proteinmedicine.symptombusinessImmunosuppressive AgentsAlimentary pharmacologytherapeutics
researchProduct

Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer.

2009

Objective This study evaluated a new chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the ARCHITECT analyzer. Design and methods Patient and laboratory proficiency samples were tested at three European sites and one site in the United States. Results The CMIA total %CV's were all < 8% and the Limit of Quantification (LOQ) was < 1.52 ng/mL across the four sites. It cross-reacts to sirolimus metabolites F4 and F5 and showed no hematocrit interference over a range of 25% to 55%. Patient specimen correlations to three LC/MS/MS methods gave R ≥ 0.91 at three sites and mean biases of 14%, 25% and 39%. CMIA patient specimen correlations to the Abbott IMx gave R ≥ 0.94 at…

Spectrum analyzerClinical BiochemistryHematocritSensitivity and Specificitylaw.inventionMagneticslawAntibody SpecificityTandem Mass SpectrometrymedicineHumansParticle SizeChemiluminescenceDetection limitImmunoassaySirolimusChromatographymedicine.diagnostic_testChemistryMulti siteGeneral MedicineImmunoassay methodImmunoassayLuminescent MeasurementsPositive biasImmunosuppressive AgentsChromatography LiquidClinical biochemistry
researchProduct

S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academ…

2016

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used 'off-label'. The aim of the present guideline was to achieve a broad consensus on treatment strategies for patients with CLE by a European subcommittee, guided by the European Dermatology Forum (EDF) and supported by the European Academy of Dermatology and Venereology (EADV). In total, 16 European participants were included in this project and agreed on all recommendations. Topical corticosteroids remain the mainstay of trea…

Systemic diseasemedicine.medical_specialtyVenereologyConsensusCalcineurin InhibitorsDermatologyDapsone030207 dermatology & venereal diseases03 medical and health sciencesAntimalarialsRetinoids0302 clinical medicineAdrenal Cortex HormonesmedicineLupus Erythematosus CutaneousHumans610 Medicine &amp; healthlupus erythematous cuteneous guidelines treatmentLenalidomideLenalidomide030203 arthritis & rheumatologyBiological ProductsLupus erythematosusbusiness.industryfungiGuidelineMycophenolic Acidmedicine.diseaseDermatologyThalidomideClinical trialThalidomideInfectious DiseasesMethotrexatePractice Guidelines as TopicbusinessDapsoneImmunosuppressive Agentsmedicine.drug
researchProduct

Mycoplasma fermentans-derived lipid inhibits class II major histocompatibility complex expression without mediation by interleukin-6, interleukin-10,…

1996

Mycoplasma cause several diseases in man and animals. Some strains can chronically infect humans, leading to fever or inflammatory syndromes such as arthritis, particularly in immunosuppressed patients. A set of pathogenicity factors shared by many mollicutes may be membrane components that activate macrophages to secrete cytokines and other inflammatory mediators. Mycoplasma-derived high molecular weight material (MDHM) is a macrophage-activating amphiphilic lipid which was purified from Mycoplasma fermentans. We studied the influence of MDHM on the expression of major histocompatibility complex (MHC) class II molecules by mouse resident peritoneal macrophages with an ELISA. Highly purifie…

T cellImmunologyAntigen presentationBiologyNitric OxideMajor histocompatibility complexMicrobiologyMiceAntigenTransforming Growth Factor betaInterferonMHC class ImedicineAnimalsImmunology and AllergyMycoplasma fermentansCells CulturedMycoplasma fermentansMice Inbred C3HInterleukin-6Tumor Necrosis Factor-alphaHistocompatibility Antigens Class IIInterleukinbiology.organism_classificationLipidsInterleukin-10Molecular WeightKineticsmedicine.anatomical_structureInterferon Type IImmunologyProstaglandinsbiology.proteinCytokinesFemaleImmunosuppressive Agentsmedicine.drugEuropean Journal of Immunology
researchProduct

Azathioprine, Mycophenolate Mofetil, and Methotrexate Specifically Modulate Cytokine Production by T Cells

1998

T-Lymphocytesmedicine.medical_treatmentAzathioprinePharmacologyMycophenolateGeneral Biochemistry Genetics and Molecular BiologyInterferon-gammaMiceHistory and Philosophy of ScienceAzathioprinemedicineAnimalsCells CulturedMice Inbred BALB CTumor Necrosis Factor-alphabusiness.industryGeneral NeuroscienceMycophenolic AcidMethotrexateCytokineCytokinesMethotrexatebusinessImmunosuppressive AgentsSpleenmedicine.drugAnnals of the New York Academy of Sciences
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells

2015

Abstract Coevolution of ticks and the vertebrate immune system has led to the development of immunosuppressive molecules that prevent immediate response of skin-resident immune cells to quickly fend off the parasite. In this article, we demonstrate that the tick-derived immunosuppressor sialostatin L restrains IL-9 production by mast cells, whereas degranulation and IL-6 expression are both unaffected. In addition, the expression of IL-1β and IRF4 is strongly reduced in the presence of sialostatin L. Correspondingly, IRF4- or IL-1R–deficient mast cells exhibit a strong impairment in IL-9 production, demonstrating the importance of IRF4 and IL-1 in the regulation of the Il9 locus in mast cel…

Transcription GeneticCell DegranulationInterleukin-1betaImmunologyBiologyArticleCell DegranulationHost-Parasite InteractionsMiceImmune systemImmunityAnimalsImmunology and AllergyInterleukin 9Mast CellsPromoter Regions GeneticMice KnockoutRegulation of gene expressionMice Inbred BALB CBinding SitesInterleukin-6Interleukin-9DegranulationReceptors Interleukin-1CystatinsAsthmaImmunity InnateMice Inbred C57BLGene Expression RegulationInterferon Regulatory FactorsImmunologySignal transductionImmunosuppressive AgentsProtein BindingSignal TransductionInterferon regulatory factors
researchProduct

Human genetic polymorphisms and risk of viral infection after solid organ transplantation.

2021

The immune system plays a key role in the host defense against viral pathogens. A signaling cascade is activated upon infection involving a variety of molecules such as pattern-recognition receptors (PRRs), interleukins or antiviral interferons. Long-term immunosuppression after solid organ transplantation (SOT) mainly abrogates adaptive T-cell-mediated responses, thus highlighting the relative contribution of innate immunity. Single-nucleotide polymorphisms (SNPs) within genes coding for PRRs or soluble mediators have been associated with differential susceptibility to viral infections among SOT recipients. A protective effect against cytomegalovirus (CMV) infection or disease has been att…

TransplantationInnate immune systembusiness.industryvirusesmedicine.medical_treatmentVaricella zoster virusImmunosuppressionHerpes SimplexDiseaseOrgan Transplantationmedicine.disease_causeAntiviral AgentsMannose-Binding LectinPolymorphism Single NucleotideTransplant RecipientsTLR2Immune systemImmunologyCytomegalovirus InfectionsGenetic predispositionmedicineHumansHuman viromebusinessImmunosuppressive AgentsTransplantation reviews (Orlando, Fla.)
researchProduct

Zizyphus lotus L. (Desf.) modulates antioxidant activity and human T-cell proliferation

2009

Abstract Background Zizyphus lotus L. (Desf.) also known as Jujube, is a deciduous shrub which belongs to Rhamnaceae family. This plant is used in Algerian traditional medicine for its anti-diabetic, sedative, analgesic, anti-inflammatory and hypoglycaemic activities. In the present study, we determined the concentrations of different vitamins (vitamin A, C and E) and fatty acids in root, stem, leaves, fruit pulp and seed of Zizyphus lotus L. (Desf.) and assessed the effects of their aqueous extracts on antioxidant status and human T-cell proliferation. Methods Aqueous filtrates from different parts, i.e, root, leaf, stem, fruit pulp and seed, of Zizyphus lotus L. (Desf.) were prepared. Vit…

VitaminAntioxidantLinolenic acidT-LymphocytesLinoleic acidmedicine.medical_treatmentGene ExpressionAscorbic AcidLymphocyte ActivationAntioxidantsCell LineLinoleic Acidchemistry.chemical_compoundBotanymedicineHumansVitamin EMicronutrientsFood scienceVitamin AbiologyVitamin CPlant ExtractsVitamin Efood and beveragesZiziphuslcsh:Other systems of medicineGeneral MedicineZiziphuslcsh:RZ201-999biology.organism_classificationAscorbic acidComplementary and alternative medicinechemistryFruitInterleukin-2Plant StructuresImmunosuppressive AgentsResearch Article
researchProduct